DIPG Clinical Trials

We Sponsor an Ongoing Study of DIPG Tissue
With about 300 DIPG cases in the U.S. each year, a lack of tumor tissue available to study had hampered research on the disease. So, we built one of the largest biobanks of DIPG samples in the U.S.

Since 2010, we’ve been working to collect and conduct molecular analysis of samples from DIPG patients including serum, cerebrospinal fluid, urine, and tumor tissue. Our goal is to characterize the genetic abnormalities that cause DIPG tumors to form and identify key biomarkers we can target with more effective treatments.

To learn about this observational study and how to enroll a patient, please call us at 202-476-5198 or email mkambhampati@childrensnational.org.

We’re Recruiting for New Trials
In addition to sponsoring the ongoing analysis of DIPG tissue samples, Children’s National is one of the hospitals involved in recruiting for several nationwide clinical trials of promising new approaches.

  • Molecular Profiling for Individualized Treatment Plan for DIPG

    This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole exome sequencing and RNA sequencing as well as predictive modeling.

  • Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma (PBTC-047)

    This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma that is growing, spreading, or getting worse (progressive). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Other Current Studies
While they are no longer recruiting, Children’s National clinicians, researchers, and patients are also involved in these multi-center trials: